Carlyle and GTCR complete AMRI acquisition
The Carlyle Group and GTCR have closed its previously announced acquisition of Albany Molecular Research Inc, a global contract research, development and manufacturing organization working with the life sciences industry. No financial terms were disclosed; however, a previous PE HUB item on the deal tagged the amount at $21.75 per share. Credit Suisse served as financial adviser to AMRI while Barclays, Bourne Partners and Morgan Stanley did likewise for Carlyle. And, RBC Capital Markets LLC served as financial adviser to GTCR.
31 August 2017•3 mins read
